Direct and Total Effectiveness of the Intranasal, Live-Attenuated, Trivalent Cold-Adapted Influenza Virus Vaccine Against the 2000-2001 Influenza A(H1N1) and B Epidemic in Healthy Children
- 1 January 2004
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Pediatrics & Adolescent Medicine
- Vol. 158 (1), 65-73
- https://doi.org/10.1001/archpedi.158.1.65
Abstract
Background The efficacy of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine (CAIV-T) against influenza A(H3N2) and B infections in healthy persons is established, but its effectiveness against natural influenza A(H1N1) infection is unknown. Objective To assess the effectiveness of CAIV-T in healthy children during the 2000-2001 influenza A(H1N1) and B epidemic. Design Community-based, nonrandomized, open-label trial from August 1998 through April 2001. Setting Intervention and comparison communities in central Texas. Participants Healthy children, aged 1.5 to 18 years, from the intervention communities received a single dose of CAIV-T at least 1 time or more in 1998, 1999, and/or 2000. Main Outcome Measures The incidence of medically attended acute respiratory illnesses during the 2000-2001 influenza epidemic was compared in 3794 health plan CAIV-T recipients with age-eligible, health plan nonrecipients in the intervention communities for direct effectiveness (n = 9325), and with those in the 2 comparison communities for total effectiveness (n = 16 264). Results The 2281 CAIV-T recipients in 2000 had significant direct protection against medically attended acute respiratory illness of 18% to 20% during the biphasic influenza A(H1N1) and B epidemic, and 17% to 26% during influenza A(H1N1) predominance. The 931 recipients of CAIV-T in 1999 containing influenza A/Beijing/262/95(H1N1) and B/Beijing/184/93–like viruses had persistent heterovariant protection against the 2000-2001 influenza A/New Caledonia/20/99(H1N1) and B/Sichuan/379/99 variants. The 616 recipients of a single CAIV-T dose in 1999 only, including those younger than 5 years with no prior natural exposure to influenza A(H1N1) viruses, showed persistent protection. Conclusion Healthy children who received CAIV-T in 2000 or 1999 were protected against new variants of influenza A(H1N1) and B in the 2000-2001 influenza epidemic.Keywords
This publication has 16 references indexed in Scilit:
- Estimating Efficacy of Trivalent, Cold-adapted, Influenza Virus Vaccine (CAIV-T) against Influenza A (H1N1) and B Using Surveillance CulturesAmerican Journal of Epidemiology, 2003
- Safety and effectiveness of the trivalent, cold-adapted influenza vaccine (CAIV-T) in childrenInternational Congress Series, 2001
- Burden of Disease—Implications for Future ResearchPublished by American Medical Association (AMA) ,2001
- Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic controlVaccine, 2000
- Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccineThe Journal of Pediatrics, 2000
- Influenza and the Rates of Hospitalization for Respiratory Disease among Infants and Young ChildrenNew England Journal of Medicine, 2000
- The Effect of Influenza on Hospitalizations, Outpatient Visits, and Courses of Antibiotics in ChildrenNew England Journal of Medicine, 2000
- Effectiveness of Live, Attenuated Intranasal Influenza Virus Vaccine in Healthy, Working AdultsJAMA, 1999
- Design and Interpretation of Vaccine Field StudiesEpidemiologic Reviews, 1999
- Emerging Infections: Pandemic InfluenzaEpidemiologic Reviews, 1996